ERNA - Company ID 0000748592
Eterna Therapeutics Inc. (ERNA) reported net income of -$14.08M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$14.08M | +68.4% |
| FY 2024 | -$44.54M | -105.6% |
| FY 2023 | -$21.67M | +11.8% |
| FY 2022 | -$24.58M | +79.9% |
| FY 2021 | -$122.55M | -1580.8% |
| FY 2020 | -$7.29M | -256.2% |
| FY 2019 | -$2.05M | -690.3% |
| FY 2018 | -$259.00K | +76.0% |
| FY 2017 |
Eterna Therapeutics Inc. (ERNA) reported net income of -$14.08M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, Eterna Therapeutics Inc.'s net income declined from -$3.42M to -$14.08M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$1.08M |
| +63.2% |
| FY 2016 | -$2.92M | +59.5% |
| FY 2015 | -$7.23M | -43.7% |
| FY 2014 | -$5.03M | -377.7% |
| FY 2013 | -$1.05M | -5.8% |
| FY 2012 | -$995.00K | +70.9% |
| FY 2011 | -$3.42M | - |